prognosis
Last reviewed 01/2018
The prognosis in myasthenia gravis is very variable. The use of immunosuppressive drugs has steadily improved outcome in recent years.
Remission or substantial improvement can be expected in 80% of patients. For those with associated thymoma, the 5 year survival is approximately 30 %.